Therefore, we speculate that CADM3 inhibits PD-L1 expression in breast cancer cells by regulating ERK protein in the MAPK pathway, thereby reducing its binding to T cells, so that T cells are released and the weakened immune function of tumor cells is restored. Here, CADM3 is linked to breast carcinoma.